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Abstract
Background: HIV-infected patients develop multiple metabolic abnormalities including insulin resistance, lipodystrophy and
dyslipidemia. Although progression of these disorders has been associated with the use of various protease inhibitors and
other antiretroviral drugs, HIV-infected individuals who have not received these treatments also develop lipid abnormalities
albeit to a lesser extent. How HIV alters lipid metabolism in an infected cell and what molecular changes are affected
through protein interaction pathways are not well-understood.
Results: Since many genetic, epigenetic, dietary and other factors influence lipid metabolism in vivo, we have chosen to
study genome-wide changes in the proteomes of a human T-cell line before and after HIV infection in order to circumvent
computational problems associated with multiple variables. Four separate experiments were conducted including one that
compared 14 different time points over a period of .3 months. By subtractive analyses of protein profiles overtime, several
hundred differentially expressed proteins were identified in HIV-infected cells by mass spectrometry and each protein was
scrutinized for its biological functions by using various bioinformatics programs. Herein, we report 18 HIV-modulated
proteins and their interaction pathways that enhance fatty acid synthesis, increase low density lipoproteins (triglycerides),
dysregulate lipid transport, oxidize lipids, and alter cellular lipid metabolism.
Conclusions: We conclude that HIV replication alone (i.e. without any influence of antiviral drugs, or other human genetic
factors), can induce novel cellular enzymes and proteins that are significantly associated with biologically relevant processes
involved in lipid synthesis, transport and metabolism (p=,0.0002–0.01). Translational and clinical studies on the newly
discovered proteins may now shed light on how some of these proteins may be useful for early diagnosis of individuals who
might be at high risk for developing lipid-related disorders. The target proteins could then be used for future studies in the
development of inhibitors for preventing lipid-metabolic anomalies. This is the first direct evidence that HIV-modulates
production of proteins that are significantly involved in disrupting the normal lipid-metabolic pathways.
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Introduction
In the past two decades, the use of highly active antiretroviral
therapy (HAART) has minimized the global incidence of the
acquired immunodeficiency syndrome (AIDS) by reducing the
viral load in HIV-infected individuals [1–4]. However, a
significant number of patients on HAART develop multiple
metabolic complications and are at high risk for developing many
chronic diseases including insulin resistance, coronary artery
disease, renal diseases, lipodystrophy and dyslipidemia to name a
few [1,2,5–14]. Although lipodystrophy is a rare disease in the
general population, it is significantly common in HIV-infected
individuals who have been treated with various combination
therapies [14–21]. In addition, many HIV-infected individuals
who have not received any treatment also develop hyperlipidemia,
hypertension, diabetes, insulin resistance, and other metabolic
complications [10,16,21].
Lipodystrophy was initially characterized as the wasting
syndrome with selective loss of body fat or lipoatrophy (thinning
of arms, legs and face) central adiposity and accumulation of fat in
the breast tissue or the back of the neck (buffalo hump) [22,23].
The clinical profile of this disease has now been expanded to
include dyslipidemia, hyperglycemia, hypercholesterolemia, hepa-
tomegaly, glomerulonephritis and other metabolic syndromes
[4,6,15,18,20,22,24–26]. Once the symptomatic disease is estab-
lished in HIV-infected patients, it is difficult to reverse the
condition in these individuals [27].
Although molecular mechanisms responsible for the numerous
lipid-related disorders in HIV-infected individuals are not well
understood , treatment with nucleoside reverse transcriptase
inhibitors (NRTI’s) has been reported to affect mitochondrial
functions by depletion of its DNA and inhibiting transcription
[27]. On the other hand, protease inhibitors (PI’s) bind to catalytic
domains of the HIV protease and inhibit virus replication
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receptor-related protein (LRP) and cytoplasmic retinoic-acid
binding protein type 1 (CRABP1), both of which show 60%
sequence homologies to HIV protease [18]. Since these proteins
regulate lipid metabolism, the binding of PI’s to LRP and
CRABP1 impairs chylomicron uptake and triglyceride clearance
[18,23]. In addition, adipocyte toxicity has also been reported due
to PI’s interference with the functions of the transcription factor
and the sterol regulatory element binding protein 1C [27].
Among the numerous cell types that are susceptible to HIV
infection in vivo, the T-cells, monocytes, macrophages, follicular
dendritic cells are primarily responsible for the enhanced
replication of the virus in the body. Although adipocytes can be
infected by HIV in vitro or in vivo, these cells are not uniformly
infected and the virus replication is slow because most adipocytes
are quiescent cells. Exposure of these cells to cytokines or other
factors produced by a variety of cell types infected by HIV (or
other pathogenic organisms) activates expression of HIV receptors
needed for the infection and replication [29–32]. Further, adipose
tissue is comprised of multiple cell types including adipocytes,
monocytes, macrophages, endothelial and vascular smooth muscle
cells [30,32,33]. These immune cells are functionally active in the
adipose tissues and produce numerous cytokines and other
regulatory factors that influence endocrine and lipid metabolism
[32,33]. The adipokines are also vital for lipid homeostasis,
regulation of steroid hormones, prostaglandin and fat soluble
vitamins [30,34,35]. These factors also control storage of excess
lipids and triglycerides (both normal and abnormal fatty acids)
present in the circulation [34,36]. Many infectious agents
including HIV have profound effects on adipocytes which become
dysfunctional and can not store most lipids /triglycerides properly.
This causes additional lipid abnormalities and metabolic disorders
in HIV-infected individuals [20,30,37]. Therefore, it is important
to note that even when adipocytes are infected by HIV in vivo, the
multiple abnormalities seen in adipose tissues of HIV-1-infected
individuals are not due to the replication of HIV in adipocytes per se.
The viral envelope and cell surface membranes are made up of
lipoproteins and cholesterols, and the fatty acids are synthesized in
the cytoplasm. Both lipids and lipoproteins are required for
molecular communication at each step of the virus replication,
from its entry into the cell to integration, transcription, assembly
and budding of virus particles from cell membranes [14,38–44].
While the bulk of lipids present in the circulation are contributed
by the dietary fats, at least eight different types of lipids are
synthesized in various cell types [30,33,37]. The lipid-binding acyl
proteins are catalyzed by a number of enzymes to make different
types and amounts of lipids that are required for the construction
of cellular membranes. Further, cholesterol efflux is a common
phenomenon in HIV-infected lymphocytes and macrophages [45–
48].When excess lipids are synthesized they are leached out from
various cell types (in circulation) and are stored in the adipocytes,
preadipocytes , undifferentiated fibroblasts or mesenchymal
connective tissue cells that are present in many organs [30,32].
Recently several investigators have used RNA expression
profiles, single nucleotide polymorphisms (SNP’s) and proteomics
technology to understand the inner workings of HIV-infected and
uninfected cells. Whereas gene expression data provides vital
genetic information [34,49–51], the mRNAs are modified post-
transcriptionally and their products are altered post-translationally
to give rise to disease-specific proteins. While a number of viral
and cellular proteins involved in cell cycle, HIV-induced syncytia
formation, apoptosis, and cytopathicity of infected macrophages
have been identified by proteomics technology [52–57], molecular
events involved in HIV-related lipid abnormalities have not yet
been studied. Since the cellular systems and cellular milieu of
proteins help in the synthesis, distribution and maintenance of
lipid homeostasis within various tissues [30,35], we chose to study
proteins involved in lipid metabolism by HIV infection alone
without any influence of the genetic diversity of HIV and the
human population it infects. A major consideration in the design
of our experiments was to circumvent numerous computational
problems associated with genetic and epigenetic variables
(smoking, alcohol, fat-rich diet, diabetes, blood pressure, diabetes
etc.) that influence lipid metabolism in vivo. Thus, we also avoided
testing proteomes of mononuclear cells derived from freshly
collected peripheral blood because the susceptibility of these
genetically diverse cells to HIV infection would be different and
the significance of variables would be difficult to assess in a
heterogeneous human population. Likewise, we did not use
primary HIV strains that are uniquely distinct as a quasispecies
in each HIV-infected individual. In addition, HIV replication as
well as disease outcomes are influenced by TNF and other
cytokines produced by many pathogenic viruses such as hepatitis,
herpes and other microbes that co-inhabit HIV infected
individuals. Since efficient replication of the virus is essential to
the disease development, we chose a single-cell clone of a human
T-cell line (RH9) that is highly susceptible to HIV infection and
studied changes in protein profiles due to infection with a
biologically cloned HIV strain B (X4) in vitro [58,59]. Cellular
proteins were analyzed by proteomics technology (two-dimension-
al gel electrophoresis (2DGE), image analyses, mass spectrometry,
bioinformatics and statistical analyses. Multiple sets of proteomes
were evaluated over a 3-year period including one experiment
which compared 13–14 different time points (starting at 1.5 hrs to
96 days post HIV-infection) over three months (see materials and
methods).
In this report we present the first direct evidence that HIV
replication alone in human T-cells, without any influence of
antiviral drugs or other factors, can stimulate production of novel
cellular enzymes and proteins that enhance fatty acid synthesis,
increase quantity of low density lipoproteins, secrete triglycerides,
dysregulate lipid transport, oxidize lipids, and alter lipid
metabolism. This data leads us to a new concept in HIV-induced
disease mechanisms.
Results and Discussion
1. Identification of Differentially Regulated Proteins Post-
HIV Infection
We have identified 18 proteins that have been differentially
regulated after HIV infection in vitro (Figure 1 & Tables 1&2).
Stringent protocols were used to select lipid associated proteins
from several hundred proteins that were upregulated, downreg-
ulated, or synthesized de novo in HIV-infected cells. All proteins
were identified by Matrix Assisted Laser Desorption Time Of
Flight (MALDI- TOF) mass spectrometry (MS) and confirmed
from multiple gels. Biological functions of each protein were
scrutinized by at least four investigators from the global public
databases and by the use of several bioinformatics programs. The
Ingenuity Systems’ knowledgebase of the ‘‘Functional Repository
of Human Genes and Proteins’’ was used to confirm proteins
involved in different aspects of human lipid metabolism. The
Ingenuity System was also used to calculate the likelihood of
whether a specific lipid-related function in the ‘‘Global Functional
Analysis’’ and ‘‘Global Canonical Pathways’’ is due to random
chance or the given biological process in lipid metabolic pathway
is statistically significant. Only those proteins that showed a p-
value of ,0.05 in relation to their effects on lipid metabolism were
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categorically associated with one or more aspects of the lipid
metabolism including the synthesis, production, secretion and
transport of various fatty acids (Figure 1).
More than 66% (12 of 18) of the identified proteins were
detected exclusively in HIV-infected cells (i.e. produced de novo
after HIV infection). These proteins were not detected in the
counterpart uninfected cells tested at different phases of cell
growth or at each of the 14 time points over a period of .3
months (Figures 2). Two of the existing proteins were upregulated
and four proteins were downregulated post-infection (Figure 3).
A functional categorization of each protein indicated that seven
proteins belonged to various families of enzymes/kinases; five were
transporter proteins, two transmembrane receptors, two molecular
chaperones, and one each of the ligand-binding and adapter-like
proteins (Tables 1& 2). The precursors of most of the secretory
proteins could be located in the cytoplasm or cytoskeleton.
Herein, we demonstrate that each of the differentially regulated
proteins (scripted in bold), is biologically relevant and has been
shown to play statistically significant role/s in cellular functions
associated with lipid metabolism.
2. Enzymes and Proteins Involved in Enhanced Fatty Acid
Synthesis
One of the most essential biological processes involved in
dyslipidemia and lipodystrophy syndrome is the accumulation of
lipids and disproportionate distribution of tissue-associated fats due
to the enhanced fatty acid synthesis. Since kinases and enzymes
activate most cellular functions including lipid synthesis, we first
analyzed the functional significance of these proteins in HIV-
infected cells in comparison with those expressed in the uninfected
control cells.
Of the 18 differentially expressed proteins in HIV-infected cells,
six enzymes/kinases were expressed exclusively in HIV-infected
cells (CO3, P3C2B, KPCB, FAS, ACSL1, and GPX1) and one
isomerase (PDIA3) was slightly downregulated after chronic HIV
infection (Table 1& Figure 3). All of these enzymes/ peptidase/
kinases have been shown to be essential for the fatty acid synthesis
as well as for numerous molecular interactions necessary for lipid
metabolism (Table 1). None of these enzymes was detected in any
of the corresponding gel-spots tested from the uninfected cells over
a long period of growth (Table 1 & Figure 2).
The complement C3 peptidase, or CO3 protein was
expressed exclusively in HIV-infected cells. This extracellular
membrane bound peptidase was not detected in any of the
numerous uninfected counterpart cells tested (Figure 2). The
complement cascade is probably activated by HIV infection since
C3- binding domains are present on HIV envelope gp120 as well
as gp41 sequences [60]. This increases the rate of infection in
different cell types of the body and contributes to HIV
pathogenesis [61,62]. Another important characteristic of the
CO3 interaction with HIV is due to the sequence identity of the
C3- activation peptide to an acylation-stimulating lipogenic
protein produced by adipocytes [36,63]. Since C3 is a primary
contact point with HIV envelope and other cell surface proteins,
the lipogenic process is most likely initiated very early in HIV
infected cells (SR unpublished data). During lipogenesis, glucose is
Figure 1. Diagram showing putative biological processes involved in lipid metabolism. Each circle represents proteins associated with the
respective function/s. Proteins in red were downregulated post-HIV infection (Figure 3). All other proteins were either expressed exclusively in HIV
infected cells (Figure 2) or upregulated after virus infection (Figure 3). Full names, abbreviations and accession numbers of each protein are listedi n
Tables 1&2.
doi:10.1371/journal.pone.0003003.g001
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glycerol to form triacylglycerols [64]. In the rat model system,
elevated levels of CO3 were shown to be critical for de novo
lipogenesis and these have been associated with liver lipodystrophy
observed during myo-inositol deficiency [65,66]. It is also
noteworthy that high levels of CO3 protein in non-HIV infected
individuals have been associated with higher lipid production, high
blood pressure and risk of cardiovascular disease [67,68]. Our
functional bioinformatics analyses identified CO3 protein to be
significantly associated with lipid-related proteins and therefore
may increase the quantity of free fatty acids (p=0.005).
Additionally, CO3 is also involved in the removal and clearance
of triacylglycerol (p=0.0002) (Table 1& Figures 1& 2).
While the HIV-infected cells showed de novo expression of
phosphatidylinositol-4-phosphate 3-kinase C2 domain-
containing beta polypeptide (P3C2B or PI3K,) at several
time points, the uninfected T-cells did not (Figure 2 & Table 1).
This membrane-bound enzyme is a major lipid messenger that
may be activated soon after binding of the viral envelope to the
plasma membrane [69]. In the initial phases of virus replication
this kinase is involved in both receptor-mediated responses and
intracellular signaling that are critical for cell survival and virus
spread [69,70]. This enzyme has been localized to the cytoplasmic
lipid bodies, which mediate signals in lymphocytes and monocytes
[71]. Furthermore, the expression of PI3K in mice with knockout
phosphatidylinositol 5-phosphate 4-kinase (beta) gene was corre-
lated with hypersensitivity to insulin [72]. These animals showed
significantly less body fat compared to the wild-type mice
indicating that PI3 kinase is essential for the lipid synthesis [72].
It is also notable that Nelfinavir, a protease inhibitor, can induce a
defect in the insulin signaling cascade downstream of the activation
of PI3-kinase in vitro [17]. These results suggest that HIV- induced
enzymes can be further modulated by antiviral treatments. Our
bioinformatics analysis indicated that the signaling activities of
PI3K /P3C2B kinase are essential for lipid synthesis and adiposity
(p=0.02).
One of the most critical enzymes for the synthesis of fatty acids
is the fatty acid synthase (FAS). This enzyme was detected
only in HIV-infected cells and was not expressed in the uninfected
counterpart T-cells (Figure 2). Recently another proteomics study
reported upregulation of FAS after HIV infection and associated
this enzyme to the dysregulation of the cell cycle post-HIV
infection [56]. FAS has multiple domains of interactions that
catalyze the formation of long-chain fatty acids and is therefore a
key lipogenic enzyme in catalyzing the terminal steps in the de novo
biogenesis of fatty acids [65,66]. An increase of FAS has been
associated with liver lipodystrophy and production of this enzyme
was suppressed by polyunsaturated fatty acids, signifying its role in
lipid synthesis and production of fatty acids [65,66]. Our
bioinformatics analysis also indicated that FAS is significantly
associated with de novo lipogenesis and enhances the synthesis of
myristate and stearic acids (p=0.02).
A multifunctional enzyme glutathione peroxidase-1
(GPX1or GSHC) was expressed in HIV-infected cells but it
was not detected in the counterpart uninfected cells (Figure 2).
This enzyme has antioxidant properties and it protects cells (and
the body) against the lethal oxidative stress [73]. Elevated levels of
GPX1 have been reported in HIV-infected adolescent and young
adults with or without antiretroviral drug treatments, both of
which cause oxidative stress [74]. In an unrelated study, cells
transfected with HIV env genes showed a 100% increase in GPX
expression [75]. Deficiency or inactivation of GPX1 has been
associated with diabetic macrovascular disease, reduced mito-
chondrial energy production and increased oxidative stress,
indicating its protective role in vivo [73,76]. These characteristics
may also be critical for maintaining cellular integrity during virus
replication (SR unpublished observations). An important property
of GPX1 related to lipid metabolism is that the quantity of this
Table 1. HIV- Modulated Enzymes and Kinases Associated with Fatty Acid Synthesis and Lipid Metabolism.
Protein Name Abbrev. Acces. # Putative Function P-value Location
Long-chain-fatty-acid-CoA ligase 1
(synonym: Acyl-CoA synthetase 1)
ACSL1 P41215 Provides activated intermediates for
complex lipid synthesis, protein
modification, and beta-oxidation
0.005 to
0.02
mitochondria/endoplasmic
reticulum/peroxisome/microsomal
membrane
Complement C3 precursor CO3 (C3) P01024 Peptidase that promotes virus infection
and fatty acid synthesis; cooperates with
other lipogenic proteins in removal
of triaclglycerols
0.0002 to
0.005
extra-cellular space
Fatty acid synthase FAS (FASN) P49327 Lipogenic enzyme:catalyzes formation
of long-chain fatty acids
0.02 cytoplasm, melanosome
Glutathione peroxidase GPX1 P07203 Antioxidant enzyme that detoxifies lipid
hydroperoxides
0.01 cytoplasm
Protein kinase C beta type KPCB (PRKCB1) P05771 Is involved in generation of
phosphatidylethanolamine, a lipid found in
biological membranes
0.01 cytoplasm, peripheral membrane
Phosphatidylinositol-4-phosphate
3-kinase C2 domain-containing
beta polypeptide
P3C2B (PIK3C2B) O00750 Lipid kinase activity– phosphorylates
phosphatidylinositol in the cell membrane
0.02 plasma membrame, cytoplasm,
microsome, nucleus
Protein disulfide isomerase A3
precursor
PDIA3* P30101 Essential for the formation of APOB;catalyzes
rearrangement of -S-S- bonds in proteins
0.02 endoplasmic reticulum lumen,
melanosome
All proteins except PDIA3 (
*) were upregulated compared to the counterpart uninfected cells or were synthesized de novo in HIV-infected cells. Protein names,
abbreviations, locations and accession numbers are from SwissProt and are presented in alphabetical order. Putative functions of each protein are related to biological
processes involved in various aspects of lipid metabolism. Significance associated with lipid metabolism was calculated by Fisher Exact Test using software from
Ingenuity Systems Inc. A p-value of ,0.05 represents a statistically significant non-random association of a specific protein with a lipid-related function in the Global
Functional Analysis.
doi:10.1371/journal.pone.0003003.t001
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major endogenous lipid peroxidation product that has been
considered as a marker of oxidative damage (SR unpublished
observations) [73,77]. Overexpression of GPX1 has also been
reported to disrupt insulin functions by quenching intracellular
reactive oxygen species required for insulin sensitivity [78]. By the
use of Ingenuity Systems’ bioinformatics programs, GPX1 was
found to be significantly associated with enhanced quantity of fatty
acids (p=0.01)(Table 1).
Among the seven de novo synthesized enzymes in HIV-infected
cells, protein kinase C, beta type (KPCB or PKC) showed
the highest peak of expression with a significance score of p=0.02
in relation to the synthesis and metabolism of lipids in humans
(Table 1; Figure 2). PKC is a phospholipid-dependent serine-
threonine kinase, which regulates the production of phosphatidyl-
ethanolamine [17,79,80]. Among the many cellular functions
associated with the expression of KPCB /PKC, the synthesis and
secretion of lipids by epithelial cells appear to be most relevant to
our research goals [81]. Overexpression of this kinase has also
been shown to cause functional changes that lead to hyperglyce-
mia, lipid-associated diabetic vascular complications, and cardio-
myopathy in humans [80,82]. Upregulation of KPCB /PKC in
eosinophils has been linked to the formation of non-nuclear lipid
bodies and induction of platelet-activating factor (PAF), which
increases the synthesis of eicosanoids (polyunsaturated fatty acids
or arachidonic acids) [83]. These data provide overwhelming
evidence that activation of PKC enzyme is essential for lipid
metabolism [82].
An interesting observation of our study was that the long-
chain-fatty-acid-CoA ligase 1 (ACSL1: synonym, acyl-
CoA synthetase) was detected within 1.5 hrs after HIV
infection, while most other differentially expressed proteins were
not quantifiable at this time. This enzyme was induced de novo after
HIV infection of T-cells in vitro and was not detected in any of the
numerous gels from the uninfected counterpart cells (Figure 2).
The lipogenic activity of this enzyme is also essential for fatty acid
metabolism in various tissues as it provides activated intermediates
for complex lipid synthesis, protein modification and beta-
oxidation [84,85]. Our statistical and bioinformatics analyses
identify ACSL1 to be critical for increased quantities of fatty acids
(p=0.02) and storage of fatty acids as triglycerides (p=0.005)
(Table 1).
The fatty acid binding protein epidermal (FABP5 or
FABPE) protein was expressed exclusively in the experimentally
HIV-infected T-cells (Figure 2; Table 2). Although a recent
proteomics study reported FABPE to be slightly downregulated
Table 2. HIV- Modulated Proteins Associated with Lipid Metabolism
Protein Name Abbrev. Acces. # Putative Function P-value Location
Acyl-CoA-binding protein ACBP* P07108 Loss or deficiency of ACBP results in fatty
acid metabolism abnormalities
0.02 cytoplasm; Ligand
Serum albumin [Precursor] ALBU (ALB) P02768 Binds to fatty acids: lipid peroxidation and
crystallization
0.01 Extra-cellular space; Transporter
Apolipoprotein A-I APOA1 P02647 Involved in reverse transport of cholesterol
from tissues; promotes cholesterol efflux
from tissues; related to ipoprotein-modifying
enzymes degrades APOB
0.03 Extra-cellular space;Transporter
Apolipoprotein B-100
[Precursor]
APOB P04114 Major protein constituent of LDL and VLDL.
Functions as a recognition signal for the
cellular binding and internalization of LDL
particles by the apoB/E receptor; only protein
to mobilize triacylglycerides
0.03 Extra-cellular space;Transporter
Fatty acid-binding protein,
epidermal
FABPE (FABP5) Q01469 High specificity for fatty acids. Involved in
biosynthesis of phosphatidylcholine and
other lipids
0.02 Adapter/Transporter
Heat shock 70 kDa protein
1-HOM
HS71L (HSPA1L) P34931 Functions in protein folding; prolongs life of
mature protein kinase C by allowing the
enzyme to re-phosphorylate
0.0002 cytoplasm; Stress-induced
Molecular Chaperone
Heat shock protein HSP
90-beta
HS90B (HSP90AB1) P08238 molecular chaperone works with HS71L 0.0002 cytoplasm, melanosome; Stress-
induced Molecular Chaperone
Low-density lipoprotein
receptor-related protein
1 precursor
LRP1 Q07954 Receptor for aggregated LDL ; increases
quantity of free fatty acids
0.0002 to 0.002 plasma membrane, cytoplasm,
nucleus; Receptor
Low-density lipoprotein
receptor-related protein
2 precursor
LRP2* P98164 Regulates lipid metabolism, modulates
multiple signaling pathways
0.02 membrane; Receptor
Stress-induced-
phosphoprotein 1
STIP1* P31948 Mediates the association of the molecular
chaperones HSC70 and HSP90;
downregulation may enhance lipid oxidation
0.0002 cytoplasm, nucleus;Adapter
Very low-density lipoprotein
receptor precursor
VLDLR P98155 Increases quantities of LDL and fatty acids;
reduces clearance of triacylglycerol-rich lipids
0.0002 to 0.01 membrane; Receptor/Transporter
The three downregulated proteins are marked with (
*). All other (n=8) proteins were either expressed exclusively in HIV-infected cells or were upregulated compared to
those detected in the uninfected cells. Protein names, abbreviations, locations and accession numbers are according to SwissProt. Putative functions and significance
scores in relation to lipid metabolism were calculated by Fisher Exact Test using software from Ingenuity Systems Inc. A p-value of ,0.05 represents a statistically
significant non-random association of a specific protein with a lipid-related function/s in the Global Functional Analysis
doi:10.1371/journal.pone.0003003.t002
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gels of uninfected cells tested at various stages of cell growth and
replication. This may be due to differences in the host cells (C33A
cervical carcinoma and PML cells) and the virus (HIV-LAI) used
in that study [57]. However, in normal physiological conditions,
FABP5 is expressed during differentiation of human skin, heart,
Figure 2. Proteins detected exclusively in HIV-infected cells by MALDI-TOF mass spectrometry from multiple gels. These proteins
were not detected in counterpart uninfected cells tested at multiple time points and various stages of cell growth. X-axis=protein names
(abbreviations) are according to SwissPROT: Y-axis=average of normalized quantity and standard deviations for each protein expressed in multiple
gels. The line limits are +/2 one standard deviation for the range of data points for each protein. Full protein names and Accession #s of each protein
are provided in Table 1.
doi:10.1371/journal.pone.0003003.g002
Figure 3. Proteins modulated by HIV post-infection. Up-regulated proteins are APOB and LRP1 and downregulated proteins are ACBP,
STIP1, LRP2, and PDIA3. X-axis=protein names (abbreviations according to SwissPROT). Each protein was detected in multiple gels. Y-Axis=average
of normalized quantities and standard deviations for each protein detected in multiple gels. The line limits are +/2 one standard deviation for the
range of data points for each protein. Full protein names and Accession #s of each protein are provided in Tables 1 & 2.
doi:10.1371/journal.pone.0003003.g003
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with high specificity, there is a breakdown in the storage of fats
during lipolysis, resulting in the release of free fatty acids into the
bloodstream [87]. An increase in the expression levels of FABP5
after HIV infection of T-cells in vitro suggests its role in producing
free fatty acids at a higher rate in these cells (p=0.02) (Figure 2
&Table 2).
3. Overexpression of Low Density Lipoproteins and their
Receptors
Our proteomics analyses indicated that the low-density
lipoprotein (LDL) receptor 1 (LRP1) was excessively
upregulated post-HIV infection with 148% higher quantity than
detected in the uninfected control cells (Table 2 and Figures 3).
This receptor is one of the most important regulators of lipid
metabolism and is involved in cell signaling, transportation, and
aggregation of lipids through a wide range of mechanisms [88–90].
Unlike the high affinity LDL receptors that bind to LDL particles
and internalize them for degradation and clearance, LRP1 binds
to multiple ligands but more specifically to aggregated LDL (AgLDL)
[88,91]. Since LRP1 is the receptor for AgLDL, it plays a
significant role in altering signal transduction pathways, and this
property distinguishes LRP1 from ‘‘classical’’ LDL receptors [92].
The aggregated AgLDL particles provoke accumulation of
cholesteryl esters and modulate adipocyte differentiation-related
proteins on the surface of lipid droplets [92]. Interaction of LRPs
with cell surface proteoglycans in vitro has been shown to induce
catabolism of triglyceride-rich lipoproteins [91]. Increased expres-
sion of LRP1 is also positively associated with increased quantity of
free fatty acids [90]. LRP1 is normally associated with macrophages
and vascular smooth muscle cells and is upregulated in lipid-
enriched plaques in atherosclerotic lesions [88,92,93]. In addition,
lipid peroxidation of low and very low density lipoproteins has
been implicated in early stages of heart diseases through multiple
potential pathways [94,95]. Overexpression of LRP1 in our
experimentally HIV infected cells exemplifies its multiple roles in
enhancing the quantity of fatty acids (p=0.02), increasing free
fatty acids (p=0.005), removal of lipids (p=0.0002) and clearance
of triacylglcerol (p=0.0005) (Table 2).
In addition to LRP1, the HIV infected cells expressed the Very
Low-Density Lipoprotein Receptors (VLDLR’s). These
receptors were not expressed in any of the uninfected cells at
different phases of growth (Figure 2 & Table 2). Bioinformatics
analysis indicated that the expression of VLDLR’s is highly
significant in increasing the quantity of fatty acids and triglycer-
ides/free fatty acids (p=0.01 & p=0.005 respectively). In addition
these receptors are essential for the transport and depletion of
lipids (p=0.0002) and clearance of triacylglycerol (p=0.0005).
The VLDLR’s bind to very low density lipoproteins and mediate
their catabolism in vitro [96]. Thus, expression of both VLDLR’s
and LRP1 would not only be expected to increase the quantities of
LDL and VLDL, but would also reduce clearance rates of very low
density lipoproteins into denser particles in both treatment-naı ¨ve
and anti-retroviral treated individuals [97–99]. This is a major
cause of lipodystrophy in HIV-infected individuals regardless of
treatments [97,100,101].
Among all the differentially regulated proteins the Apolipo-
protein-B100 (APOB) showed the highest quantity with a
1327% increase after HIV infection compared to the minimum
detectable levels present in uninfected (control) cells (Figure 3).
The APOB is associated with the low density lipoproteins (LDL),
intermediate density lipoproteins (IDL), and very low density
lipoproteins (VLDL) particles. In both treated and untreated HIV
patients, the APOB, VLDL and IDL have been associated with
fractional clearance rates [97,98,102]. Expression of APOB is
clinically significant as it assembles atherogenic lipoproteins
involved in plaque formation [103]. Functional bioinformatics
analysis indicated that APOB enhances the quantity of both the
cell-associated and cell-free fatty acids (p=0.01 & p=0.005
respectively). In addition, this protein increases secretion and
mobilization of various cholesterols (triacylglycerols) in coopera-
tion with apolipoprotein A1 (p=0.01). In vitro studies have also
indicated that the lipidation of APOB results in the conversion of
LDL from HDL to VLDL [104]. An increase in LDL subclass B has
also been associated with perturbation of lipid metabolism and
dysregulation of triglycerides in patients with AIDS suggesting its
role in progression of cholesterol-associated metabolic abnormal-
ities [105].
In HIV-infected cells apolipoprotein-A1 (APOA1) was
synthesized de novo post-HIV infection and it was not detected in
any of the multiple samples tested from the uninfected counterpart
cells (Figure 2 & Table 2). Although, APOA1 has been considered
as a major protein component associated with high density
lipoprotein (HDL) or ‘‘good’’ cholesterol [106], our bioinformatics
analyses using Ingenuity’s Global Functional Analysis programs
indicate that APOA1 is one of the most active proteins that
performs multiple functions in lipid metabolism, all of which are
statistically significant p-value (p=0.02) (Figure 1). For example,
APOA1 by itself is sufficient for recruitment of cholesterol and
sphingomyelin; depletion of phosphatidylcholine; mobilization and
translocation of cholesterol; secretion of lysophosphatidylcholine
and cholesterols. In cooperation with LRP1, APOA1 helps in the
transport of cholesterol esters (p=0.002). Coordinated expression
of APOA1 with C3 (CO3), LRP1, and VLDLR in HIV infected
cells is highly significant in the removal of lipids (p=0.0002). All of
these proteins (LRP1, C3 and VLDLR) were co-expressed and
excessively upregulated in our experimentally HIV infected cells
suggesting their functional interactions (Table 1 and Figure 2). The
activated APOA1 also has a proteolytic enzyme activity which is
capable of degrading APOB-100 into smaller fragments [107].
Thus, an amphipathic peptide analogue of APOA1 has been
reported to inhibit cell fusion in both herpes simplex virus (HSV)
and HIV infected cells [108,109]. Specific subclasses of APOA1
have also been effective in enhancing cholesterol efflux from cells
in various phases of reverse cholesterol transport [106].
In an unrelated proteomics-based study, detection of APOA1 in
the plasma of HIV-infected individuals was considered a
‘‘biomarker for HIV diagnosis’’ in patients with AIDS. The
‘‘diagnostic’’ significance of APOA1 needs to be further studied as
these patients had AIDS and some were on HAART for 2 months
[110]. However, it is evident that APOA1 is synthesized de novo in
the experimentally HIV infected cells without any influence of
additional factors. These data indicate that the biological functions
of this protein are more versatile than previously envisioned and
the multiple roles played by APOA1 in different aspects of lipid
metabolism are highly significant (p=0.0001 to 0.02).
4. Lipid Oxidation and Crystallization
An unexpected finding of our proteomics study was that
significant amounts of albumin (ALBU) precursor protein were
synthesized de novo in HIV-infected cells i.e. not detected in any of
the uninfected counterpart cells in wide range of growth phases
over a period of .3 months (Figure 2). Albumin is a major
multifunctional secretory/transporter protein that binds to hor-
mones, bilirubin, drugs, a variety of elements Ca (2+), Na (+), K (+)
and other molecules present in the plasma [111]. The human
ALBU also binds to fatty acids with high affinity as it has several
polymorphic forms with long hydrophobic pockets that are
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this protein [111,112]. The binding of ALBU to fatty acids
regulates enzymes that metabolize, esterify and crystallize lipids
[113]. The upregulation of ALBU, a ‘‘normal’’ protein is therefore
highly significant (p=0.02) as it plays a significant role in
crystallization of cholesterol. The high affinity binding of fatty
acids to ALBU in vivo, also results in excessive secretion of APOB,
leaving fatty acids unavailable for lipoprotein assembly in
hepatocytes [114]. The HIV-infected individuals who show higher
LDL levels in the plasma also have albuminaemia indicating
coordinated upregulation of ALBU with increased lipid profiles
[5]. In the present study expression of lipogenic proteins correlated
with the expression of ALBU in HIV-infected cells (Figure 2 &
Table 2). Another most relevant finding related to our experi-
mental results was that binding of ALBU to the complement C3
protein results in the formation of microbubbles that adhere to
vascular endothelium and accelerate atherosclerotic processes
[115]. As noted earlier, both ALBU and the C3 proteins were
expressed only in HIV-infected cells and these proteins were not
detected in uninfected cells, suggesting their putative co-operative
roles in inducing lipid abnormalities (Figure 2).
5. Effects of Downregulated Proteins on Lipid
Metabolism
The differential proteomics analyses of HIV-infected and
uninfected cells identified four proteins (ACBP, PDIA3, STIP1
& LRP2) that were downregulated post-HIV-infection (Figure 3).
Functional bioinformatics analyses indicated that suppression of
these proteins could be associated with increased production of
proteins that enhance lipid synthesis and quantity (Figure 1). For
example, Acyl-CoA binding protein (ACBP) is a key protein
that modulates the long- chain fatty acyl-coenzyme-A (Acyl-CoA)
metabolism [116]. This protein is normally induced during
adipocyte differentiation and its downregulation inhibits adipocyte
differentiation which results in growth arrest and adipocyte cell
death [117]. The slight decrease in the expression of ACBP in
HIV infected cells (Figure 3) suggests that downregulation of this
protein may be potentially harmful for adipocyte differentiation in
vivo. ACBP also facilitates esterification of long-chain fatty acids
with coenzyme (Acyl-CoA) which is the first step in fatty acid
metabolism [116]. Depletion of this protein in cells has been
shown to result in abnormalities of lipid metabolism, particularly
those involved in fatty acyl-CoA long chain formation [116,118].
Loss of ACBP also leads to triacylglycerol biosynthesis abnormal-
ities as it binds long-chain fatty acyl-CoA esters and facilitates its
transportation [118,119]. The downregulation of ACBP therefore
significantly enhances abnormalities and mobilization of triglyc-
erides (p=0.02).
The quantity of protein disulphide isomerase (PDIA3),
previously known as phosphoinositol-specific phospholi-
pase C was about 9% lower in HIV-infected cells than the
uninfected cells (i.e.downregulated) (Figure 3). Although in another
study, PDIA3A was shown to be upregulated 2.43-fold after
42 hours of ‘‘massive’’ (high multiplicity of HIV infection), this
may be due to variations in the HIV strain (LAI clone) used for
this study, the macrophage tropism of the virus, the cells used to
grow the virus ( C33A human cervical carcinoma monolayer cells
and PM1 T cells) [57,120]. While the expresssion of PDIA3A was
initially reported to be important in the reproductive tract and
placenta [121], this peptidase is shown to be critical for disulfide
bond formation of newly synthesized proteins [119,122]. PDIA3
also plays an important role in signal transduction from the cell
surface receptor to other parts of the cells including the nucleus
and endoplasmic reticulum [121]. This protein is identical to the
beta subunit of the microsomal triacylglycerol transfer protein
(MTP), which is a multifunctional protein essential for the
assembly, folding, and secretion of APOB-containing lipoproteins
[119,122,123]. The absence or downregulation of the beta subunit
may cause defective secretion of APOB-containing lipoproteins,
which would then promote development of beta-lipoproteinemia,
an autosomal recessive disease [122,123]. During lipid metabo-
lism, PDIA3A is also significantly associated with the cleavage of
phosphatidylinositol (p=0.02).
The stress-induced-phosphoprotein 1 (STIP1) was down-
regulated post-HIV infection (Figure 3). This is a co-chaperone or
an adapter for the human heat shock proteins (HSPs) Hsp70/
Hsp90 (or HS7H and HS9B) machinery which organizes
complex interactions with other proteins [124,125]. Both HS7H
and HS9B were upregulated exclusively in HIV-infected T-cells and
were not expressed in uninfected cells (Figure 2; Table 2). In general
these proteins are expressed in response to the endogenous stress
and they protect cells from injury (i.e. inhibit apoptosis) [126,127].
In physiologic conditions, coordinated expression of HS7H and
HS9B stabilizes preexisting proteins against aggregate formation
and they mediate correct folding and maturation of newly
synthesized cellular proteins [126,128,129]. During the assembly
of multicomponent complexes, HS7H and HS9B alter conforma-
tions of substrate proteins as and when needed for specific signal
transductions [130]. HS7H and HS9B are hormone binding
proteins and proper assembly of their complexes with progesterone
and glucocorticoid receptors depend on the transcriptional
activation subsequent to hormone binding [131–134]. In an
experimental model both progestin and androgen were shown to
enhance production of triglycerides particularly after the induction
of fatty acid synthetase in cells [135].
An important and pertinent function relevant to our experimen-
tal model is that Hsp70 binds to the activated protein kinase C
(PKC) and prolongs the life of the mature kinase by allowing the
enzyme to re-phosphorylate [126,136]. As discussed earlier, PKC
(KPCB) was overexpressed in HIV infected cells (Figure 2) and it is
an essential enzyme for the generation and regulation of
phosphatidylethanolamine that activates diacylglycerol
[82,126,136]. Any disruption of this interaction would prevent re-
phosphorylation of PKC which is essential for multiple functions
including fatty acid synthesis. It is therefore not surprising that both
HS7H /HS9B complex and PKC were induced de novo after HIV
infection. The relationship of these proteins to lipid metabolism was
scored to be highly significant (p=0.0002).
The LDL receptor-related protein 2 (LRP2) was down-
regulated in HIV-infected cells 3 hrs post- infection (Figure 3 &
Table 2). This is a multi-ligand receptor (megalin) and it
participates in a wide range of physiological functions, including
protection against atherosclerosis [89]. Downregulation of LRP2
in HIV-infected cells with concomitant upregulation of LRP1
suggests an enhanced production of lipid aggregates and related
abnormalities.
6. Statistical Significance of Protein Interaction Pathways
All biological processes are regulated by interactions of proteins
with other proteins, lipids, lipoproteins, RNA or DNA in order to
perform specific cellular functions. Although a complete network
of all possible protein-protein interactions in the cell is difficult to
visualize, we have constructed protein-interaction pathways of 18
proteins that were identified to be significantly associated with
different aspects of lipid metabolism (p-values ranging from 0.0002
to 0.01;Tables 1 and 2).
Two different programs were used to construct interaction
pathways (Ingenuity Pathway Analysis (IPA) Systems and
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programs generated conceptually similar pathways, the interaction
diagrams presented here were created by Strategene Pathway
Architect according to the instructions provided by the manufac-
turers (Figure 4).
Using the IPA’s bioinformatics programs which integrate the
physical, biochemical and biological properties of proteins, we
have created tentative scenarios for the 18 proteins whose
expression or suppression has been significantly associated with
putative steps or functions involved in lipid metabolism
(p=,0.0002–0.01) (Figure 1). Among the 18 differentially
regulated proteins produced in response to HIV infection, FAS,
FABPE, KPCB, and P3C2B enzymes/kinases have been shown to
be essential for the synthesis and production of fatty acids; the
multifunctional molecular chaperon machinery (HS71L/ HS90B)
protects PKC kinase and prolongs the life of this enzyme in the cell
while preventing other newly synthesized proteins from incorrect
folding [126]. Binding of HS71L/ HS90B proteins to progesterone
receptors generates signals for the production of triglyceride in the
cell [135]. The upregulation of APOB, CO3, LRP1, VLDLR,
GPX1, and ACSL1 and slight downregulation of LRP2 have been
associated with increased quantities of free fatty acids; the
overproduction of APOB and de novo synthesis of APOA1 are
associated with higher lipid secretion; upregulation and concom-
itant expression of APOA1, LRP1, VLDLR, and CO3/C3 is
critical for lipid depletion, clearance and transport; APOB,
together with slightly downregulated ACBP, mobilizes the fatty
acids and produces triacylglycerol abnormalities. Production of
ALBU esterifies, crystallizes and produces aggregated or oxidized
lipids /cholesterols.
An increased production of APOB-100, VLDLR, and LRP1 in
HIV-infected cells also indicates that multiple lipid metabolic
Figure 4. Protein-interaction pathways of proteins associated with various aspects of lipid metabolism. The functional significance of
each protein was defined using Ingenuity bioinformatics platforms designed for Systems Analyses of genes and protein expressed in human health
and disease. All proteins were uploaded into the Strategene Pathway Architect (SPA) program and protein-interaction pathways were constructed
according to the manufacturer’s instructions. Proteins identified by our present proteomics studies are shown with blue outlines; purple-colored
proteins are enzymes and kinases and pink-colored (with blue outlines) are other significant proteins involved in the lipid metabolism. Lines
connecting proteins indicate molecular networks of interactions. The greater the number of lines originating from a protein, the more significant the
molecular interactions of that protein with other protein/s. Note the extensive networks of interactions between all proteins identified in the present
study (blue circles), particularly those of APOB and APOA-1. Full protein names, abbreviations and accession numbers of each protein are listed in
Tables 1&2.
doi:10.1371/journal.pone.0003003.g004
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interactions may induce physiological changes related to lipid
metabolism and cholesterol homeostasis, as well as formation of
aggregated lipids that bind to LRP1 (Figures 1 & 4). As the
production of lipid- inducing proteins increases, the numbers of
receptors for these ligands are also augmented and new signal
transduction molecules are activated. This cascade of events would
result in a breakdown of multiple metabolic pathways, especially in
HIV-infected individuals.
7. Antiretroviral Drug does not affect Production of
Apolipoproteins
One of the most significant proteins associated with many lipid
related diseases is APOB-100 (p=0.01 to 0.005). As indicated
earlier, this protein was excessively upregulated in HIV-infected
cells post HIV-infection (Figure 3). Presence of APOB promotes
cholesterol efflux and it is absolutely essential for the metabolism of
low-density lipoproteins (LDL), the intermediate density lipopro-
teins (IDL) and the very low-density lipoproteins (VLDL). To
validate the sensitivity and specificity of our proteomics technology
and the functionality of both viral and cellular proteins, we
analyzed the expression of the critical APOB protein in HIV
infected, uninfected and counterpart cells treated with an inhibitor
and antiviral drug azidothymidine (AZT or Zidovudine). This
drug has been shown to inhibit HIV replication in vitro and is used
in combination with other drugs to treat HIV patients [137,138].
As can be seen in the three sequential gel images of Figure 5,
APOB is NOT inhibited by treatment of HIV-infected cells by
Zidovudine while HIV p24, the major gag protein is inhibited. As
expected, the HIV-infected cells expressed P24 and the uninfected
cells did not. These results not only validate our techniques but
also indicate that cellular pathways for the synthesis of APOB are
distinct from those of HIV replication (Figures 4 & 5).
8. Conclusions
We conclude that the replication of HIV alone in human T-
cells modulates synthesis of novel enzymes, kinases and other
proteins that enhance fatty acid synthesis, increase lipid peroxi-
dation (crystallization), disrupt lipid metabolism and reduce lipid
clearance. Since HIV-modulated proteins were isolated by a rapid
extraction technique and fractionated without the use of any
affinity purification techniques such as protein-specific ligands or
antibodies, we believe this unbiased proteomics approach has led
to the discovery of novel proteins that have not been identified
previously in HIV-infected cells.
Our data provides direct evidence that HIV infection alone can
induce a number of novel lipid-associated proteins without any
influence of genetic or epigenetic factors that influence metabolic
events in vivo. Although APOB and VLDL, IDL have been
associated with fractional lipid clearance rates in HIV-infected
individuals [97,98,102], expression of proteins involved in different
aspects of lipid metabolism has not been reported. We have
validated our techniques and demonstrated that treatment of
HIV-infected cells with antiviral drug Zidovudine does not inhibit
the production of APOB, one of the most critical lipid associated
proteins while the HIV replication is inhibited (Figure 5). APOB is
a secretory globin-like protein (lipoprotein ) responsible for
carrying LDL, which supplies cholesterol to the tissues. Excess
lipids are transported through the blood by lipoproteins and are
stored in adipocytes. In HIV-infected individuals both protease
inhibitors and nucleoside reverse transcriptase inhibitors such as
AZT (Zidovudine) have been shown to have detrimental effects on
adipose tissue, liver, and muscle [6,7,18,22].
Bioinformatics and protein- interaction pathway analyses of the
18 differentially regulated proteins indicated that these proteins
are biologically relevant as many have been reported in non-HIV
infected patients with hyperlipidemia and other lipid-related
disorders. In vivo the chronically HIV-infected cells produce many
secretory cytokines/factors that bind to adipocytes and other cell
types (bone marrow, connective tissue, mesenchymal stem cells
and others) resulting in enhanced signaling for the production of
fatty acids and lipid-regulatory enzymes. Since lipids themselves
are excellent signal- transduction molecules, they can bind to cells
nonspecifically and induce new signals in both infected and
Figure 5. Figure 5: Two-dimensional gel electrophoresis patterns of HIV-infected and counterpart uninfected cells T-cells. Protein
profiles were evaluated 48 hours after treatment with azidothymidine (AZT), or mock treatment with phosphate buffered saline. Figure 5A represents
protein profile of uninfected T-cells and shows theexpression of Apolipoprotein B-100 (APOB) and the absence of HIV p24 antigen. Figure 5B
represents the protein profile of HIV-infected T-cells and displays the presence of both APOB and p24 antigen. Figure 5C indicates that APOB is NOT
inhibited by treatment of HIV-infected cells by AZT while the viral proteins are inhibited by the antiviral drug.
doi:10.1371/journal.pone.0003003.g005
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lipid-related diseases are apparent in vivo.
Translational studies using knockout mice and characterization
of the newly discovered proteins by testing the effects of small
interfering RNA (RNAi) or small- molecule inhibitors in vitro would
help in identification of most prevalent, functionally relevant and
statistically significant biomarkers for early diagnosis of individuals
who might be at high risk for developing lipid-related disorders.
Future studies may lead to innovative strategies for developing
better therapeutics or inhibitors for preventing lipid-related
metabolic disorders.
This is the first study to experimentally demonstrate correlation
between HIV replication and de novo expression and/or upregula-
tion of proteins that enhance production of key proteins involved
in lipid metabolism.
Materials and Methods
The primary goal of this study was to apply proteomics-based
approaches to study HIV-modulated protein profiles overtime
under controlled conditions in vitro. The study circumvented
problems associated with numerous environmental and genetic
factors that influence HIV infection, lipid production and disease
progression in vivo.
Cell Cultures and HIV Infection
To address some of the basic questions related to the virus-host
cell interactions, we conducted several labor-intensive proteomics
studies to identify proteins modulated by HIV infection alone.
Each step of these studies, from sample preparation to data
analyses, has been quality- controlled in order to understand the
complexities of HIV replication. A T-cell line (RH9) was chosen
because HIV replication in these cells is highly efficient and both
the HIV and the cell are clonal derivatives. The genome-wide
protein profiles solely in response to HIV infection of cells in vitro
were evaluated without any additional supplements or factors that
may possibly influence lipid functions. Cells were grown in RPMI
medium containing 10% fetal bovine serum and 2mM glutamine
with no antibiotics or any cytokine [58].
Approximately 6–7610
8 cells were suspended at a concentration
of 2610
6 cells/ml of medium containing 2 ug/ml polybrene. After
24 hrs, one aliquot of 2610
7 cells was removed as a ‘‘baseline
control’’ and remainder of cells were divided equally into two large,
125 cm flasks. One set of cultures was infected in vitro with a
biological clone of HIV-1(X4 strain) at a multiplicity of infection of
one (MOI=1) while the counterpart uninfected cells were
maintained as the experimental control. Cultures were incubated
at 37uC in a humidified atmosphere of 5% CO2. After 90 minutes,
both sets of cultures were transferred to centrifuge tubes to spin
down cells and to remove the medium and /or the virus. All cells
were washed once with fresh medium and transferred to new flasks.
At this time(i.e. after 1.5 hours), an aliquotof 2610
7 cells from each
culture was removed for analysis and the rest of the cells were
incubated as before. Subsequently, both the HIV-infected and
uninfected (control) cell samples were collected at multiple time
points up to 96 days (i.e. different stages of infection and cell growth
at 3 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr, 96 hr, 6 days (d), 10 d,
15 d, 26 d, 47 d and 96 d post-infection . In addition, we tested at
least ten different infected and uninfected sets of cells between 10–
26 daysof infectionand two separate aliquots grown over a 3 month
period from an uncloned culture of the same cell line (H9) that was
infected with the X4 HIV strain in 1990’s. This culture has been
maintained in our laboratory in vitro as a chronically infected, virus-
productive cell line.
Supernatants of all cell cultures were harvested for protein
analyses, regardless of their time of collection and were tested for
the presence of HIV P24 antigen (Abbott’s HIV-p24 antigen test).
Two- Dimensional Gel Electrophoresis (2DGE) and Image
Analysis
Proteins were extracted from approximately 2610
7 cells from
each of the infected and uninfected sets of cultures at each time
point using differential extraction procedures established in our lab
[139]. Cell pellets were briefly washed twice for 5 minutes each in
the phosphate buffered saline (PBS) to remove serum and other
pertinacious material, followed by a second wash in Tris
(hydroxymethyl)aminomethane. Cells were then solubilized by a
sequential two-step procedure using two separate reagent
concentrations (5–8 M urea, 2–4% CHAPS, 2 M thiourea and
other nonionic and zwitterionic detergents with 2.5%carrier
ampholytes and protease inhibitor cocktail (BioRad)). The
solubilization steps were modified by a rapid lysis technique (10–
15 seconds followed by 2 seconds’ sonication) according to our
laboratory’s standardized protocols [139]. The first fraction
contained the most soluble membrane proteins followed by other
membrane, cytoplasmic, and nuclear protein fractions [139]. Each
sample was analyzed by isoelectric focusing (IEF), two-dimensional
gel electrophoresis (2DGE), image analysis, and Matrix Assisted
Laser Desorption Time Of Flight (MALDI- TOF) mass spec-
trometry as described below.
For IEF, protein fractions were clarified by centrifugation at
100,0006g, and the supernatant was analyzed in the first
dimension on a pH gradient of 3–10. Each IEF strip containing
separated proteins was then analyzed by 2-dimensional gel
electrophoresis (2-DGE) on 6–18% gradients of SDS-polyacryl-
amide gels. To analyze low abundant proteins, cell lysates were
separated by IEF on different overlapping pH gradients (3–10, 4–7
and 5–8) and then size fractionated by molecular weight using
2DGE on different gradient gels. Each of the HIV-infected and
uninfected counterpart samples collected overtime were processed
and run at the same time under identical conditions using a 12-gel
electrophoresis tank. For quality control, a gel from a lyophilized-
reconstituted sample of E. coli proteins was used as a general
standard, and one each of the best gels from HIV-infected and
counterpart uninfected samples was used as experimental
(i.e.HIV-infected and uninfected cells) reference standard with
each run.
Proteins were visualized by staining with Coomassie Blue. Some
gels containing proteins of interest were also counterstained with
Amido or silver black after scanning the images of the Coomassie-
stained gels. However, since silver black was not compatible with
MS, we used Sypro Ruby red which gave distinctive signals for
proteins that were present in both gels but displayed different
expression levels. Digitized images of each gel were obtained by
CCD camera and protein spots in each of the uninfected and
infected samples were analyzed by the use of Melanie and
PDQuest softwares. Identical parameters were used for all gel
scans including those of the standards and controls against which
each image was aligned and matched automatically. Each spot in
the uninfected controls was compared with the corresponding spot
in gels from the counterpart HIV-infected cells. The software was
designed to correct differences in the gel staining according to the
algorithms that integrate the optical densities (OD) of each pixel in
the spot area and then evaluated normalized quantities against all
standardized spot images. Spot intensities were set to differ in the
normalized quantities by a factor of 2 compared to the relative
average of one group to that of the other. In addition, each gel was
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necessary.
Expression or suppression of many differentially expressed
proteins was confirmed in separate experiments carried out over a
period of approximately 3 years; one experiment was conducted
with time point analyses (1.5 hours to 96 days) over a period of 3
months and in subsequent experiments samples were harvested on
specific time points ranging from 10–26 days. Although many
differentially regulated proteins were detected as early as 1.5 hrs
post infection and at several successive time points, most proteins
in 1.5 to 4 hrs’ gels were not quantifiable due to small quantities.
For detailed analyses, we selected 33 gels from a large number of
gels run on different IEF (pH 3–10 & 4–7) and SDS -PAGE
gradients. These included at different time points ranging from
1.5 hours to 96 days plus numerous samples from 10–26 days as
these samples yielded higher quantities and were detected in
multiple gels. As indicated earlier, we also used chronically HIV-
infected cells and control uninfected cells as standard references
for all gels.
All proteins from HIV-infected cells were compared with those
expressed in the uninfected counterpart cells at different time
points. Only those proteins that were reproducibly detected in
multiple gels were selected for bioinformatics and statistical
analyses. To obtain a more accurate dataset for each of the
upregulated or downregulated protein in HIV-infected cells we
calculated standard deviations of the mean values from the range
of normalized quantities expressed in both HIV-infected and
uninfected samples tested. A plus and minus one standard
deviation of the mean value is illustrated by a bar within the
graph for each protein (Figures 2 and 3).
MALDI-TOF Mass Spectrometry (MS)
All differentially regulated spots (i.e. upregulated, downregulat-
ed or de novo synthesized proteins post-HIV infection) and some
common spots present both in the infected and uninfected cells
were selected for protein identification by MALDI-TOF MS. All
spots were excised form gels and washed successively with water,
ammonium bicarbonate (25 mM, 1:1(v/v) acetylnitrite
(ACN):25 mM ammonium bicarbomnate), and 100% ACN. The
gels were then vacuum-dried and stored in the refrigerator until
MS was performed. Prior to MS the dried gels were reconstituted
in 25 mM ammonium bicarbonate containing 0.1 mg ultra-pure,
MS-grade trypsin (pH 7.8) (Promega) and incubated overnight to
extract peptides. Peptide fingerprints of in-gel digests were
analyzed by MALDI-TOF-MS according to the manufacturer’s
protocols (Applied Biosystems). All annotated spectra were
analyzed using PS1 software (Applied Biosystems) and MASCOT
(Matrix Science, London). Embedded in these programs are
biostatistical and analytical systems to select differentially ex-
pressed peaks (MS signals). The search parameters included
mammals and human. All spectra were linearly calibrated using a
two-point calibration with internal standards corresponding to
autoproteolytic tryptic peaks. To quantify the differences in
calibration between the reference spots and experimental protein
spots on the plate, we applied the derived ‘topological map’ to
afford the best calibration throughout the plate while using a single
calibrant.
Validation of Protein Functionality by the use of an HIV-
Inhibitor
To validate the functionality of both viral and cellular proteins
expressed in HIV-infected cells, we tested the same H9 T- cells
described above and infected these with the same X4 HIV strain
that was used for all proteomics studies. Cells were divided into
two aliquots; one was infected with HIV and the other was used as
uninfected control. The virus in the supernatant was removed after
3 days and cells were placed in new flask after washing with PBS.
Each set of cultures was then divided into 4 flasks each (i. e. 8
flasks); two each (i.e. duplicates) of the HIV-infected and
uninfected (control) cultures were maintained as experimental
controls and separate replicates of each were treated with10 ug/ml
of Azidothymidine (AZT or Zidovudine) a reverse transcriptase
inhibitor (gift from GlaxoSmithKline/Burroughs Wellcome). This
drug has been shown to inhibit HIV replication in vitro and has
been used to treat HIV infected individuals alone and in
combination with other drugs [137,138]. After 48 hrs, proteins
were extracted from all cultures as described above and all samples
from the treated, untreated, HIV- infected and uninfected
counterpart cultures were tested by proteomics analyses as
described above.
The ability of HIV to replicate or to be inhibited by AZT was
tested by the presence or absence of p24 antigen in the
supernatant and in the cellular protein fractions by proteomics
technology (Figure 5). No HIV p24 was detected in HIV-infected
cells treated with AZT whereas HIV-infected untreated cells
produced significant quantities of this protein indicating that HIV
replication was inhibited and the proteomics results are significant.
Further, since the expression of APOB protein was not affected by
the antiviral drug treatment it indicated that both low abundant
p24 and high abundant proteins can be detected by our
proteomics technology.
Statistical Analyses and Protein- Interaction pathways
involved in Lipid Metabolism
The significance of proteins involved in lipid metabolism was
possible only by analyzing massive amounts of data on HIV-
modulated cellular proteomes overtime for a very long period.
Several hundred differentially expressed proteins (upregulated or
downregulated or de novo synthesized proteins post-HIV infection)
were identified by proteomics analyses and each was categorized
according to the known function/s in the global databases of
human proteins (UniProt/SwissProt). Standard deviations of mean
values were calculated for each protein quantity and are
represented by bars within the graph (Figure 2 & 3). By the use
of bioinformatics and computational program ‘‘Functional Re-
pository of Humans Genes and Proteins’’ (Ingenuity Systems Inc.),
biological functions of each protein were validated in relation to
the proteins involved in lipid synthesis, production, quantity,
cleavage, transport, secretion, and/or lipid oxidation. These
programs also calculated the likelihood of whether a particular
function in ‘‘Global Functional Analysis and Global Canonical
Pathways’’ was due to a random chance or a set of proteins
identified experimentally could be statistically associated with
specific biological processes involved in lipid metabolism.
Using 262 contingency tables, the p-values of all experimentally
identified proteins were calculated by the Global Functional
Analysis programs in relation to the total number of proteins that
have been shown to be associated with human lipid metabolism.
The p-values of proteins involved in the lipid metabolism were
calculated by using the right-tailed Fisher Exact Test and
Ingenuity Pathway Analysis Systems. These analyses identified a
coordinated expression of 18 proteins with statistical significance (p
values =,0.05 as indicators) in relation to global and local lipid
metabolism-related functions. However, All proteins selected for
this study had p-values ,0.02.
For protein-interaction pathway analyses, we have used the
Ingenuity Pathway Analysis (IPA) System and Strategene Pathway
Architect (SPA) software. All 18 proteins involved in the lipid
HIV Lipid Metabolism
PLoS ONE | www.plosone.org 12 August 2008 | Volume 3 | Issue 8 | e3003metabolism were used to construct the pathways according to
manufacturer’s instructions. One of the pathways made by the
SPA is presented in Figures 4.
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